Money Makers podcast: 01 Nov 2025
In this edition of the Money Makers Investment Trusts Podcast, Jonathan Davis, editor of the Investment Trusts Handbook and winner of the AIC Best Broadcast Journalist Award for two years running (2024 and 2025), takes a look at the biotech sector and speaks to Woody Stileman, London officer manager at RTW Biotech, managers of RTW Biotech Opportunities (RTW); Geoffrey Hsu, manager of Biotech Growth Trust (IBT); and Ailsa Craig, co-manager of International Biotechnology Trust (BIOG).
You can listen to this podcast in full on the audio player below. Alternatively, you can subscribe via our YouTube channel and most podcast platforms, including Apple Podcasts, Spotify, Amazon Music and Soundcloud. You can also find us listed on The AIC’s Podcast Directory. We are grateful to J.P. Morgan Asset Management, whose no-strings support enables us to keep the podcast free and our editorial integrity intact.
If you enjoy the Investment Trusts Podcast, you may also find value in joining The Money Makers Circle. This membership scheme offers subscribers an opportunity to receive additional premium content, including interviews, investment trust performance data, market/portfolio reviews and regular extracts from the editor’s notebook. This week, as well as the usual features, the Circle features a profile of Seraphim Space Investment Trust (SSIT). Future profiles include Scottish American (SAIN) and Impax Environmental Markets (IEM). Our new expanded weekly subscriber email includes a comprehensive summary of all the latest news, plus the week’s biggest share price, NAV and discount movements. Subscribe and you will never miss any important developments from the sector. A subscription costs £12 a month, or £120 for one year with a two week free trial.
303: Woody Stileman, Geoffrey Hsu, Ailsa Craig
0:02:47 – Woody Stileman – RTW Biotech (RTW)
0:03:13 – Why have biotech trusts been out of favour?
0:08:39 – The involvement of AI
0:10:45 – Appointments to the US Health Department and FDA
0:13:44 – Drug pricing
0:18:33 – RTW’s private holdings and the IPO drought
0:22:13 – The trust’s discount
0:29:24 – Risks in biotech
0:31:16 – A short break
0:32:22 – Geoffrey Hsu – Biotech Growth Trust (BIOG)
0:32:37 – Explaining the biotech resurgence
0:40:25 – Risks from an accelerated pipeline
0:41:42 – The selling points of BIOG
0:44:32 – Investing in China
0:47:18 – UK interest in the sector
0:48:34 – Ailsa Craig – International Biotechnology Trust (IBT)
0:48:56 – Looking at the changing fortunes of the biotechnology sector
0:54:26 – The IBT difference to other trusts in the sector
0:57:09 – The impact of the US drive to reduce drug prices
0:59:31 – New drugs originating from biotech
1:03:26 – Playing the China theme
1:04:53 – Best use of capital
1:06:01 – Capability of returns and position in the cycle
1:07:44 – The change of management house
1:09:08 – Close
We are an editorially independent research and publishing venture committed to providing high-quality investment information and resources. You can sign up below to be notified about the latest podcasts by email as soon as they become available. Please note that the podcasts should not be regarded as personal financial advice, but are provided for information and background only. We are very grateful for your continued support and the enthusiastic response to our more than 300 podcasts in the over five years since launch!.
Disclosures about the editor’s holdings of investment trusts can be found here. Our podcasts are also available on the Association of Investment Companies website (www.theaic.co.uk). The producer of the podcasts is the brilliant Ben Gamblin – more details on him here.